The information provided in this article is for educational and informational purposes only and does not constitute legal, financial, or tax advice. No attorney-client relationship is formed by reading this content. Laws and regulations vary by jurisdiction and change frequently; always consult with a qualified professional regarding your specific situation. The author and publisher assume no liability for any actions taken based on this information.
Key Facts
- Federal level: In October 2011, the FTC and DOJ issued a final joint antitrust policy statement for Accountable Care Organizations tied to the Medicare Shared Savings Program.
- Federal level: The 2011 ACO policy statement described a safety zone tied to combined Primary Service Area (PSA) shares, including a 30% combined threshold for each common service in a participant’s PSA.
- Federal level: The 2011 ACO policy statement framed its safety-zone concept as a limit on when the Agencies would challenge, absent extraordinary circumstances.
- Federal level: In July 2023, the FTC announced withdrawal of the health-care antitrust policy statements as outdated, and DOJ described withdrawn guidance as non-binding and not creating legal rights or obligations.
- Federal level: The FTC/DOJ 2000 competitor collaboration guidelines distinguish per se illegal agreements (like price fixing or market allocation) from rule-of-reason analysis for other agreements.
- Federal level: The 2000 competitor collaboration guidelines also describe a general safety-zone screen that, absent extraordinary circumstances, applies when collective market shares do not exceed 20%.
- National overview: Federal antitrust standards provide one baseline, while state competition rules and enforcement practices vary by state.
- Federal level: HSR premerger notification comes from 15 U.S.C. § 18a, and the FTC describes that parties may not close until the waiting period passes or early termination is granted.
Last reviewed: May 2026. Legal rules, forms, deadlines, and procedures can change by jurisdiction, agency, and court system.
- What this archive recovery covers and what it does not
- Federal antitrust law sets the baseline for “competition” questions
- Why healthcare organizations became a recurring antitrust topic
- The 2011 FTC/DOJ ACO policy statement as historical guidance
- Current legal status the Agencies withdrew the health care antitrust policy statements in 2023
- Competitor collaborations when agreements look per se illegal versus rule of reason
- Mergers and hospital combinations the federal framework and its limits
- How HSR premerger notification connects to federal merger review
- Federal and state competition rules still intersect, but they do not match
- Bottom line for interpreting the 2012 ABA “hot topics” theme
- Sources
What this archive recovery covers and what it does not
The original 2012 “hot topics” page tied to the ABA conference could not be retrieved during this archive recovery run, so this write-up does not quote the inaccessible ABA conference’s specific content. Instead, it uses verified federal antitrust in healthcare authorities to explain why U.S. antitrust agencies focused on healthcare collaborations, mergers, and related competitive risk concepts around that time, without treating the archive item as current law. For readers interested in additional ABA archive material, TheFirstFile maintains an ABA annual meeting archive coverage page that reflects how the ABA has historically reported on legal developments.
Federal antitrust law sets the baseline for “competition” questions
Federal antitrust law generally examines restraints of trade and their effect on competition in relevant markets. Section 1 of the Sherman Act declares that certain contracts, combinations, or conspiracies in restraint of trade are “declared to be illegal,” and it includes felony penalty language in the statute text (as reflected in 15 U.S.C. § 1).
Why healthcare organizations became a recurring antitrust topic
Healthcare markets often involve structured relationships among providers, payers, and facilities. Those structures can raise antitrust questions when they operate in ways that resemble competition-reducing coordination—such as coordinated pricing or referral patterns. In that context, the federal agencies developed written policy statements and enforcement frameworks focused on particular healthcare collaboration models, including Accountable Care Organizations (ACOs).
The 2011 FTC/DOJ ACO policy statement as historical guidance
The October 2011 ACO policy statement (issued jointly by the FTC and DOJ) provided antitrust clarity about how the Agencies would address competitive concerns raised by certain new ACO arrangements. Within that historical framework, the safety-zone concept used combined Primary Service Area (PSA) market-share thresholds as an eligibility screen. The FTC’s 2011 announcement describes a safety zone where an ACO must have a combined share of 30% or less of each common service in each participant’s PSA, and the DOJ’s policy statement explains that the Agencies would not challenge ACOs that fall within that safety zone absent extraordinary circumstances.
The 2011 policy statement also described an optional expedited review concept described as a 90-day review by the Agencies for newly formed ACOs seeking additional antitrust guidance. Even though this was written as policy for that specific healthcare model, the Agencies later withdrew key parts of their healthcare policy statements as outdated.
Current legal status the Agencies withdrew the health care antitrust policy statements in 2023
FTC and DOJ later withdrew key health-care antitrust policy statements described as outdated. The FTC’s July 2023 announcement states it withdrew two health-care antitrust policy statements related to enforcement in health care markets, including the idea that certain parts no longer reflect market realities, while also stating the FTC would continue enforcement by evaluating issues on a case-by-case basis. DOJ’s withdrawal announcement likewise states that the guidance documents were non-binding and do not create legal rights or obligations.
Taken together, these 2023 withdrawal sources place the 2011 ACO safety-zone discussion in an archive-recovery posture: it explains how the Agencies framed antitrust risk for a specific ACO model at that time, but it does not operate as a current binding “safe harbor.”
Competitor collaborations when agreements look per se illegal versus rule of reason
Outside ACOs, healthcare transactions can also raise antitrust questions through competitor collaboration structures. The FTC/DOJ 2000 Antitrust Guidelines for Collaborations Among Competitors distinguish categories of agreements that receive per se treatment from those analyzed under the rule of reason. The guidelines describe certain agreements—such as agreements among competitors to fix prices or output, rig bids, or share or divide markets—as per se illegal, while agreements not treated as per se illegal are evaluated under the rule of reason.
The guidelines also describe a competitor-collaboration safety zone: absent extraordinary circumstances, the Agencies do not challenge a competitor collaboration when the collaboration and its participants collectively account for no more than 20% of each relevant market in which competition may be affected.
| Collaboration topic | How the guidelines describe analysis |
|---|---|
| Price/output fixing, bid rigging, or market allocation | Per se illegal categories |
| Other agreements among competitors | Rule-of-reason analysis |
| Safety-zone screen (market-share screen) | No challenge described when collective shares do not exceed 20% absent extraordinary circumstances |
Mergers and hospital combinations the federal framework and its limits
Healthcare consolidation can also trigger federal merger review. The 2023 Merger Guidelines describe the procedures and enforcement practices the Agencies most often use to investigate whether mergers violate the antitrust laws, and they state the Guidelines create no independent rights or obligations. The Guidelines’ structural framework uses concentration indicators, including example thresholds that treat markets with HHI greater than 1,800 as highly concentrated and HHI changes of more than 100 points as a significant increase.
In statutory terms, merger risk can also be framed through the Clayton Act’s acquisition standards. Section 18 of the Clayton Act addresses acquisitions where the effect “may be substantially to lessen competition, or to tend to create a monopoly,” which provides a statutory backbone for how merger antitrust risk is assessed in federal law.
How HSR premerger notification connects to federal merger review
For many covered mergers and acquisitions, federal law includes a premerger notification and waiting-period structure under the Hart-Scott-Rodino (HSR) Act. Under 15 U.S.C. § 18a, the waiting period ends on the 30th day after receipt (or the 15th day for cash tender offers).
The FTC’s Premerger Notification Program page describes that premerger notification involves completing an HSR Form and that the parties may not close their deal until the waiting period passes or the government grants early termination. In this archive-recovery context, the HSR framework functions as a statutory timing and program-administration concept, not a healthcare-only policy model.
Federal and state competition rules still intersect, but they do not match
Antitrust in healthcare is not only a federal question. State competition rules and enforcement practices can differ in ways that matter for enforcement and private litigation theories. Federal authorities discussed here provide baseline framing for federal antitrust standards, while state rules vary.
Bottom line for interpreting the 2012 ABA “hot topics” theme
A 2012 conference theme about antitrust in healthcare can still help modern readers understand why federal agencies paid close attention to healthcare collaborations, competitor-collaboration frameworks, and consolidation risk concepts. The most important “current-status” insight from the official record is that several specific health-care antitrust policy statements—published earlier and including the 2011 ACO statement—were withdrawn as outdated in 2023, while federal antitrust enforcement continues to operate through the governing statutes and updated enforcement frameworks.
Sources
- FTC and DOJ issue final ACO antitrust policy statement (2011)
- DOJ FTC final ACO policy statement (2011 PDF)
- FTC withdraws health-care antitrust policy statements (2023)
- DOJ withdrawal announcement and non-binding guidance statement
- 2000 competitor collaboration guidelines
- 2023 Merger Guidelines (DOJ and FTC)
- 15 U.S.C. § 1
- 15 U.S.C. § 18
- 15 U.S.C. § 18a
- FTC premerger notification program overview
